Doms № 1 -2022

Doms № 3 -2022

Hypoglycemia in patients with COVID-19: an incidental clinical finding or a normal outcome of treatment?

Mankovskyi B.M., Halushko O.A., Protsiuk O.V., Pogorila O.I.

Shupyk National University of Health Care of Ukraine, Kyiv, Ukraine


Abstract. Hypoglycemia is a common complication of diabetes mellitus (DM), which also complicates the course of COVID-19. The purpose of the work is to analyze the available scientific information on the causes and risk factors of hypoglycemia during the treatment of patients with COVID-19.

Materials and methods. A search and analysis of full-text articles was carried out in the PubMed, Web of Science, Google Scholar, and Scopus databases. The search was conducted using the key terms: “hypoglycaemia in COVID-19 patients”, “treatment of COVID-19 and hypoglycemia”, “vaccination against COVID-19 and hypoglycemia” from the beginning of the pandemic in December 2019 to July 1, 2022.

The results. The analysis of literary sources showed that hypoglycemia can occur when using drugs from many pharmacotherapeutic groups used for the treatment and vaccination of patients with COVID-19. In addition, patients with DM often have chronic complications that contribute to the occurrence of hypoglycemia in the event of a disease with COVID-19. The lockdown during the COVID-19 pandemic has further complicated the problem of hypoglycemia by restricting access to food, clinics, health services and medicines.

Conclusions: Hypoglycemia can be an incidental clinical finding. But it can also be a natural consequence of treatment if it is carried out without taking into account the possible hypoglycemic effects of drugs and without careful monitoring of the patient’s condition. In the case of determining the program of treatment and vaccination against COVID-19 in patients with diabetes mellitus, the known and possible hypoglycemic effects of drugs and vaccines should be taken into account, the level of glycemia should be carefully controlled, sudden changes in the type and dose of drugs, polypharmacy and the use of dangerous combinations of drugs should be avoided.

Key words: COVID-19, hypoglycemia, treatment, vaccination, prevention.




  1. Coronavirus (COVID-19) data. [cited 2022 July 27]. Available from:
  2. Pathan F, Selim S, Fariduddin M, Rahman MH, Ashrafuzzaman SM, Afsana F, Qureshi NK, Hossain T, Saifuddin M, Kamrul-Hasan AB, Mir AS; BES Diabetes and COVID Task Force. Bangladesh Endocrine Society (BES) Position Statement for Management of Diabetes and Other Endocrine Diseases in Patients with COVID-19. Diabetes Metab Syndr Obes. 2021 May 18;14:2217-2228. doi: 10.2147/DMSO.S293688.
  3. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: A report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005; 28. – Р.1245-1249.
  4. American Diabetes Association Professional Practice Committee; 6. Glycemic Targets: Standards of Medical Care in Diabetes—2022. Diabetes Care 1 January 2022; 45 (Supplement_1): S83–S96.
  5. Shah K, Tiwaskar M, Chawla P, Kale M, Deshmane R, Sowani A. Hypoglycemia at the time of Covid-19 pandemic. Diabetes Metab Syndr. 2020 Sep-Oct;14(5):1143-1146. doi: 10.1016/j.dsx.2020.07.003.
  6. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Martín-Quirós A, Caraco Y, Williams-Diaz A, Brown ML, Du J, Pedley A, Assaid C, Strizki J, Grobler JA, Shamsuddin HH, Tipping R, Wan H, Paschke A, Butterton JR, Johnson MG, De Anda C; MOVe-OUT Study Group. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044.
  7. Parise R, Deruiter J, Ren J, Govindarajulu M, Ramesh S, Nadar RM, Moore T, Dhanasekaran M. Impact of COVID-19 therapy on hyperglycemia. Diab Vasc Dis Res. 2022 May-Jun;19(3):14791641221095091. doi: 10.1177/14791641221095091.
  8. Siemieniuk RA, Bartoszko JJ, Zeraatkar D, Kum E, Qasim A, Martinez JPD, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020 Jul 30;370:m2980. doi: 10.1136/bmj.m2980.
  9. Marfella R, Paolisso P, Sardu C, Bergamaschi L, D’Angelo EC, Barbieri M, Rizzo MR, Messina V, Maggi P, Coppola N, Pizzi C, Biffi M, Viale P, Galié N, Paolisso G. Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients. Diabetes Metab. 2020 Oct;46(5):403-405. doi: 10.1016/j.diabet.2020.05.005.
  10. Pal R, Bhadada SK. COVID-19 and diabetes mellitus: An unholy interaction of two pandemics. Diabetes Metab Syndr. 2020 Jul-Aug;14(4):513-517. doi: 10.1016/j.dsx.2020.04.049.
  11. Mahmoud AB, Alghriany AA, Shakor AB. The effect of chloroquine induced hypoglycemia on the levels of major blood serum proteins in diabetic mice. Egypt Acad J Biol Sci C Physiol Mol Biol, 2014, Volume 6, Issue 2:138-148. doi: 10.21608/EAJBSC.2014.16041
  12. Baretić M. Case report of chloroquine therapy and hypoglycaemia in type 1 diabetes: What should we have in mind during the COVID-19 pandemic? Diabetes Metab Syndr. 2020 Jul-Aug;14(4):355-356. doi: 10.1016/j.dsx.2020.04.014.
  13. Hage MP, Al-Badri MR, Azar ST. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Ther Adv Endocrinol Metab. 2014 Aug;5(4):77-85. doi: 10.1177/2042018814547204.
  14. Abdulrahman A, AlSayed I, AlMadhi M, AlArayed J, Mohammed SJ, Sharif AK, Alansari K, AlAwadhi AI, AlQahtani M. The Efficacy and Safety of Hydroxychloroquine in Patients with COVID-19: A Multicenter National Retrospective Cohort. Infect Dis Ther. 2021 Mar;10(1):439-455. doi: 10.1007/s40121-021-00397-8.
  15. Kaur K, Kaushal S, Kaushal IG. Therapeutic status of hydroxychloroquine in COVID-19: A review. J Anaesthesiol Clin Pharmacol. 2020 Aug;36(Suppl 1):S160-S165. doi: 10.4103/joacp.JOACP_313_20.
  16. Imanova Yaghji N, Kan EK, Akcan S, Colak R, Atmaca A. Hydroxychloroquine Sulfate Related Hypoglycemia In A Non-Diabetic COVİD-19 Patient: A Case Report and Literature Review. Postgrad Med. 2021 Jun;133(5):548-551. doi: 10.1080/00325481.2021.1889820.
  17. Douin DJ, Krause M, Williams C, Tanabe K, Fernandez-Bustamante A, Quaye AN, Ginde AA, Bartels K. Corticosteroid Administration and Impaired Glycemic Control in Mechanically Ventilated COVID-19 Patients. Semin Cardiothorac Vasc Anesth. 2022 Mar;26(1):32-40. doi: 10.1177/10892532211043313.
  18. Strongin LG, Nekrasova TA, Belikina DV, Korneva KG, Petrov AV. [Dysglycemia in COVID-19 and Type 2 Diabetes Mellitus: Peculiarities of the Glycemic Profile in Hospitalized Patients and the Role of Steroid-Induced Disorders]. Probl Endokrinol (Mosk). 2022 Feb 22;68(2):56-65. Russian. doi: 10.14341/probl12840.
  19. Chou HW, Wang JL, Chang CH, Lee JJ, Shau WY, Lai MS. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan. Clin Infect Dis. 2013 Oct;57(7):971-80. doi: 10.1093/cid/cit439.
  20. Mangkuliguna G, Glenardi, Natalia, Pramono LA. Efficacy and Safety of Azithromycin for the Treatment of COVID-19: A Systematic Review and Meta-analysis. Tuberc Respir Dis (Seoul). 2021 Oct;84(4):299-316. doi: 10.4046/trd.2021.0075.
  21. Abbas HM, Al-Jumaili AA, Nassir KF, Al-Obaidy MW, Al Jubouri AM, Dakhil BD, Abdulelah MM, Al Khames QA. Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A natural clinical trial. Int J Clin Pract. 2021 Apr;75(4):e13856. doi: 10.1111/ijcp.13856.
  22. Giaime P, Guenoun M, Pedinielli N, Narbonne H, Bergounioux JP, Solas C, Guilhaumou R, Sampol J, Ollier J, Sichez H, Serveaux M, Brunner F, Bataille S. Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection. Nephrol Dial Transplant. 2020 Aug 1;35(8):1346-1353. doi: 10.1093/ndt/gfaa191.
  23. Karampela I, Dalamaga M. Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19? Arch Med Res. 2020 Oct;51(7):741-742. doi: 10.1016/j.arcmed.2020.06.004.
  24. Althaqafi A, Ali M, Alzahrani Y, Ming LC, Hussain Z. How Safe are Fluoroquinolones for Diabetic Patients? A Systematic Review of Dysglycemic and Neuropathic Effects of Fluoroquinolones. Ther Clin Risk Manag. 2021 Oct 13;17:1083-1090. doi: 10.2147/TCRM.S284171.
  25. Levine M, Stellpflug SJ, Pizon AF, Peak DA, Villano J, Wiegand T, Dib C, Thomas SH. Hypoglycemia and lactic acidosis outperform King’s College criteria for predicting death or transplant in acetaminophen toxic patients. Clin Toxicol (Phila). 2018 Jul;56(7):622-625. doi: 10.1080/15563650.2017.1420193.
  26. Mahadevan SB, McKiernan PJ, Davies P, Kelly DA. Paracetamol induced hepatotoxicity. Arch Dis Child. 2006 Jul;91(7):598-603. doi: 10.1136/adc.2005.076836.
  27. Sibiya N, Mbatha B, Arineitwe C, Onyekwuluje C, Ngubane P, Khathi A. Covid 19 May Limit the Use of Anti-hyperglycemic Agents. Does it Call for the Development of New Anti-hyperglycemic Agents? Curr Diabetes Rev. 2022;18(3):e060821195364. doi: 10.2174/1573399817666210806114200.
  28. Ray CY, Wu VC, Wang CL, Tu HT, Huang YT, Kuo CF, Chang SH. Hypoglycemia Associated With Drug-Drug Interactions in Patients With Type 2 Diabetes Mellitus Using Dipeptidylpeptidase-4 Inhibitors. Front Pharmacol. 2021 Apr 15;12:570835. doi: 10.3389/fphar.2021.570835.
  29. Elshimy G, Techathaveewat P, Alsayed M, Jyothinagaram S, Correa R. Simple Reason for Hypoglycemia: ACE Inhibitor-induced Severe Recurrent Hypoglycemia in a Nondiabetic Patient. Cureus. 2019 Aug 21;11(8):e5449. doi: 10.7759/cureus.5449.
  30. Hee Nam Y, Brensinger CM, Bilker WB, Flory JH, Leonard CE, Hennessy S. Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. Clin Pharmacol Ther. 2022 Jan;111(1):218-226. doi: 10.1002/cpt.2377.
  31. Lim, S.; Bae, J.H.; Kwon, H.-S.; Nauck, M.A. COVID-19 and diabetes mellitus: From pathophysiology to clinical management. Nat. Rev. Endocrinol. 2021, 17, 11-30.
  32. di Mauro G, Mascolo A, Longo M, Maiorino MI, Scappaticcio L, Bellastella G, Esposito K, Capuano A. European Safety Analysis of mRNA and Viral Vector COVID-19 Vaccines on Glucose Metabolism Events. Pharmaceuticals (Basel). 2022 May 27;15(6):677. doi: 10.3390/ph15060677.
  33. Bunders MJ, Altfeld M. Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions. Immunity. 2020 Sep 15;53(3):487-495. doi: 10.1016/j.immuni.2020.08.003.
  34. Trostle ME, Limaye MA, Avtushka V, Lighter JL, Penfield CA, Roman AS. COVID-19 vaccination in pregnancy: early experience from a single institution. Am J Obstet Gynecol MFM. 2021 Nov;3(6):100464. doi: 10.1016/j.ajogmf.2021.100464.
  35. Corcillo A, Cohen S, Game D, Karalliedde J. High prevalence of Afro-Caribbean ethnicity and hypoglycaemia in patients with diabetes and end stage renal disease hospitalized with COVID-19. Nephrology (Carlton). 2021 Mar;26(3):252-254. doi: 10.1111/nep.13809.
  36. Makarem J, Naghibi N, Beigmohammadi MT, Foroumandi M, Mehrpooya M. A Case Report of Progressive Liver Failure Inappropriate to Decompensated Heart Failure Following Infection With COVID-19. Cureus. 2020 Aug 30;12(8):e10142. doi: 10.7759/cureus.10142.
  37. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020 Mar 31:e3319. doi:10.1002/dmrr.3319.
  38. Klonoff DC, Messler JC, Umpierrez GE, Peng L, Booth R, Crowe J, Garrett V, McFarland R, Pasquel FJ. Association Between Achieving Inpatient Glycemic Control and Clinical Outcomes in Hospitalized Patients With COVID-19: A Multicenter, Retrospective Hospital-Based Analysis. Diabetes Care. 2021 Feb;44(2):578-585. doi: 10.2337/dc20-1857.
  39. Piarulli F, Lapolla A. COVID 19 and low-glucose levels: Is there a link? Diabetes Res Clin Pract. 2020 Aug;166:108283. doi: 10.1016/j.diabres.2020.108283.
  40. Zhang B. Expert Consensus on Telemedicine Management of Diabetes (2020 Edition). Int J Endocrinol. 2021 Mar 24;2021:6643491. doi: 10.1155/2021/6643491.
  41. Kesavadev J, Misra A, Saboo B, Aravind SR, Hussain A, Czupryniak L, Raz I. Blood glucose levels should be considered as a new vital sign indicative of prognosis during hospitalization. Diabetes Metab Syndr. 2021 Jan-Feb; 15(1): 221-227. doi: 10.1016/j.dsx.2020.12.032.
  42. Maddaloni E, Buzzetti R. Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes Metab Res Rev. 2020 Mar 31:e33213321. doi: 10.1002/dmrr.3321.
  43. Orioli L, Hermans MP, Thissen JP, Maiter D, Vandeleene B, Yombi JC. COVID-19 in diabetic patients: related risks and specifics of management. Ann Endocrinol (Paris). 2020 May 12. pii: S0003-4266(20)30068-8. doi: 10.1016/j.ando.2020.05.001.
  44. Drucker DJ. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev. 2020 Apr 15. doi: 10.1210/endrev/bnaa011.
  45. Kshanti IA, Epriliawati M, Mokoagow MI, Nasarudin J, Magfira N. The Impact of COVID-19 Lockdown on Diabetes Complication and Diabetes Management in People With Diabetes in Indonesia. J Prim Care Community Health. 2021 Jan-Dec;12:21501327211044888. doi: 10.1177/21501327211044888.
  46. Ratzki-Leewing AA, Ryan BL, Buchenberger JD, Dickens JW, Black JE, Harris SB. COVID-19 hinterland: surveilling the self-reported impacts of the pandemic on diabetes management in the USA (cross-sectional results of the iNPHORM study). BMJ Open. 2021 Sep 2;11(9):e049782. doi: 10.1136/bmjopen-2021-049782.